Publications by authors named "Han Saem Son"
Acta Pharm Sin B
March 2020
Article Synopsis
- Bone diseases like osteoporosis and periodontitis are linked to high levels of osteoclast activity and inflammation.
- Benzydamine (BA) is a non-steroidal anti-inflammatory drug that reduces pro-inflammatory cytokines, but its effects on osteoclasts were previously unclear.
- This study found that BA inhibits osteoclast differentiation by suppressing IL-1 production and enhances osteoblast differentiation, indicating its potential as a treatment for inflammation-related bone diseases and postmenopausal osteoporosis.
View Article and Find Full Text PDF
Article Synopsis
- The study focuses on skullcapflavone II (SFII), a flavonoid known for its anti-inflammatory effects, and its role in controlling osteoclasts, which are cells that contribute to bone diseases like osteoporosis and rheumatoid arthritis.
- SFII was found to inhibit osteoclast formation and activity by affecting key signaling pathways, decreasing reactive oxygen species (ROS), and modulating the integrin pathway, which governs cell survival and function.
- The findings suggest that SFII has potential as a therapeutic agent for treating and preventing bone diseases linked to excessive osteoclast activity by targeting specific cellular mechanisms.
View Article and Find Full Text PDF